Joseph J. Park
A5100764640- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Renal cell carcinoma treatment
- Chronic Myeloid Leukemia Treatments
- Hormonal and reproductive studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Immune Cell Function and Interaction
- Multiple and Secondary Primary Cancers
- Neuroinflammation and Neurodegeneration Mechanisms
- Cytomegalovirus and herpesvirus research
- Radiopharmaceutical Chemistry and Applications
- Pancreatic and Hepatic Oncology Research
- Neurogenesis and neuroplasticity mechanisms
- Genetic factors in colorectal cancer
- DNA Repair Mechanisms
- Ocular Diseases and Behçet’s Syndrome
- melanin and skin pigmentation
- Ethics in Clinical Research
- Acute Ischemic Stroke Management
University of Michigan
2020-2024
Duke University
2024
TESLA (Czechia)
2024
Duke Medical Center
2024
Cornell University
2020-2022
Swim Across America
2022
Memorial Sloan Kettering Cancer Center
2017-2022
Princeton University
2016
National Cancer Institute
2013
Royal Brisbane and Women's Hospital
2012
Importance Recent large infarct thrombectomy trials used heterogeneous imaging modalities and time windows for patient selection. Noncontrast computed tomographic (CT) scan is the most common stroke approach. It remains uncertain whether effective patients with infarcts identified using noncontrast CT alone within 24 hours of onset. Objective To evaluate effect in a on Design, Setting, Participants Open-label, blinded–end point, bayesian-adaptive randomized trial interim analyses early...
PURPOSE There are limited data available on the real-world patterns of molecular testing in men with advanced prostate cancer. We thus sought to evaluate next-generation sequencing (NGS) United States, focused single versus serial NGS testing, different disease states (hormone-sensitive v castration-resistant, metastatic vs nonmetastatic), tissue plasma circulating tumor DNA (ctDNA) assays, and how often actionable were found each test. METHODS The Prostate Cancer Precision Medicine...
Abstract Purpose: HOXB13 is an androgen receptor (AR) coregulator specifically expressed in cells of prostatic lineage. We sought to associate circulating tumor cell (CTC) expression with outcomes men mCRPC treated abiraterone or enzalutamide. Experimental Design: conducted a retrospective analysis the multicenter prospective PROPHECY trial (NCT02269982, n = 118) abiraterone/enzalutamide. CTC detection and complementary DNA (cDNA) was measured using modified Adnatest, grouping patients into...
Proteins of the major histocompatibility complex class I (MHCI) negatively regulate synapse density in developing vertebrate brain (Glynn et al., 2011; Elmer 2013; Lee 2014), but underlying mechanisms remain largely unknown. Here we identify a novel MHCI signaling pathway that involves inhibition known synapse-promoting factor, insulin receptor. Dominant-negative receptor constructs decrease Xenopus visual system (Chiu 2008), and activation increases dendritic spine mouse hippocampal neurons...
Background: Stereotactic body radiation therapy (SBRT) is an emerging treatment option for unresectable pancreatic cancer, and postulated to be more effective less toxic than conventionally fractionated intensity modulated (IMRT).Material methods: We retrospectively reviewed stage I–III adenocarcinoma treated from 2008 2016 at our institution with SBRT (five fractions, 30–33 Gy) or IMRT (25–28 45–56 Gy concurrent chemotherapy). Groups were compared respect overall survival (OS), local...
The majority of JAK2 V617F -negative myeloproliferative neoplasms (MPNs) have disease-initiating frameshift mutations in calreticulin ( CALR ), resulting a common carboxyl-terminal mutant fragment (CALR MUT representing an attractive source neoantigens for cancer vaccines. However, studies shown that -specific T cells are rare patients with MPN unknown reasons. We examined class I major histocompatibility complex (MHC-I) allele frequencies from two independent cohorts. observed MHC-I alleles...
PURPOSE Outcomes data for DNA-damaging therapeutics men with prostate cancer (PC) and non- BRCA1/2 homologous recombination repair (HRR) mutations are limited. We evaluated outcomes by HRR alteration in PC treated poly(ADP-ribose)polymerase inhibitors (PARPi) and/or platinum chemotherapy. METHODS Retrospective from the PROMISE consortium were used. Clinical differences assessed between patients BRCA1/ 2 (cohort A) those without direct BRCA complex interaction B: ATM, CDK12, CHEK1, CHEK2,...
Objectives To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients Methods We performed a retrospective cohort study collecting clinicopathological, treatment, outcome data for aUC ICIs from 2013 to 2020 across 24 institutions. compared objective response rate (ORR), overall survival (OS), progression‐free (PFS) UC (UTUC, LTUC). Uni‐...
Black men have higher incidence and mortality from prostate cancer. Whether precision oncology disparities affect with metastatic castration-resistant cancer (mCRPC) is unknown.To compare medicine data outcomes between White mCRPC.This retrospective cohort study used collected by the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium, a multi-institutional registry linked clinicogenomic data, April 2020 to December 2021. Participants included...
Abstract Background AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance these context ARTA treatment clinical outcomes remains unclear. Methods Patients with castration-resistant prostate cancer (CRPC) who had undergone genomic testing received were identified Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) database. stratified according timing...
Cytomegalovirus (CMV) retinitis characteristically causes peripheral with associated vasculitis. It rarely begins in the macula or macular necrosis exclusively. We report a case of unilateral CMV 65-year-old immunosuppressed patient and document changes during treatment through optical coherence tomography (OCT).
Abstract Corticoteroid‐induced glaucoma can result from either topical or systemic corticosteroid use. Compared with adults, the response in children is less well known. The case reported of a child who developed after receiving corticosteroids following scleral reinforcement procedure. raised intraocular pressure was controlled cessation and use antiglaucoma therapy. As many forms corticosteroids are widely used, on should have regular measurements as part their management.
Immune checkpoint inhibitors (CPIs) were recently approved in advanced clear cell renal carcinoma (RCC) and could be a promising option for metastatic RCC with sarcomatoid differentiation (sRCC) which otherwise carry poor prognosis. We sought to compare outcomes between patients who received immunotherapy (IO) including CPIs or high dose interleukin-2 (HD IL2) sRCC versus those did not. performed single-center retrospective data analysis of 44 consecutive any percentage from our...
328 Background: Anti-PD1/PDL1 immune checkpoint inhibition (CPI) is active in advanced clear cell RCC, but not all patients benefit. Preclinical studies with the combination of hypomethylating agents and CPI resulted reversal evasion tumor regression. We examined agent guadecitabine (subcutaneously on Days 1-5), anti-PDL1 antibody durvalumab (intravenously at flat dose 1500 mg Day 8) 28 day cycles RCC a single arm trial. Methods: In phase Ib portion (n=6; presented previously), dosing 45...
To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients advanced urothelial carcinoma (aUC) who have vs not undergone radical surgery (RS) or radiation therapy (RT) prior to developing metastatic disease.We performed a retrospective cohort study collecting clinicopathological, treatment and data for aUC receiving ICIs across 25 institutions. We compared (observed response rate [ORR], progression-free survival [PFS], overall [OS]) between...
Abstract Background: AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance these context ARTA treatment clinical outcomes remains unclear. Methods: Patients with castration-resistant prostate cancer (CRPC) who had undergone genomic testing received were identified Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) database. stratified according timing...